title: Shrimp anti-lipopolysaccharide factor (SALF), an antimicrobial peptide, inhibits proinflammatory cytokine expressions through the MAPK and NF-κB pathways in LPS-induced HeLa cells.
abstract: Recently, an antimicrobial peptide (AMP), the shrimp anti-lipopolysaccharide factor (SALF), was shown to act against vaginal pathogens as demonstrated by a minimum inhibitory concentration (MIC) assay and suggested that the SALF might play a protective role in orchestrating various defensive responses. The demonstration of a protective role of the SALF in cervical cancer epithelial cells (HeLa cells) led us to investigate the anti-inflammatory effects of the SALF by determining its inhibitory effects on proinflammatory markers in LPS-stimulated cervical cancer HeLa cells. The SALF was shown to inhibit the production of inflammatory cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-1α, and monocyte chemoattractant protein (MCP)-1 according to an ELISA analysis. The SALF also suppressed mRNA levels of il-6, il-8, il-1α, and mcp-1 according to an RT-PCR. We also found that the SALF might regulate vaginal epithelial cell immune responses through the MAPK and NF-κB pathways. These findings suggest that the SALF is a potential drug candidate for treating chronic inflammatory diseases, such as urethritis, vaginitis, cervicitis, and pelvic inflammatory diseases.
authors.affiliation: Department of Biochemical Science and Technology, National Taiwan University, 1 Roosevelt Road, Section 4, Taipei 10617, Taiwan.
authors.forename: Ming-Ching
authors.initials: MC
authors.lastname: Lin
authors.forename: Chieh-Yu
authors.initials: CY
authors.lastname: Pan
authors.forename: Cho-Fat
authors.initials: CF
authors.lastname: Hui
authors.forename: Jyh-Yih
authors.initials: JY
authors.lastname: Chen
authors.forename: Jen-Leih
authors.initials: JL
authors.lastname: Wu
mesh_terms: D060829:Arthropod Proteins / Q000008:administration & dosage*; D018932:Chemokine CCL2 / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D006367:HeLa Cells; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D053582:Interleukin-1alpha / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000633:toxicity; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010446:Peptide Fragments / Q000008:administration & dosage*; D010455:Peptides / Q000008:administration & dosage*; D015398:Signal Transduction / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D060829:Arthropod Proteins; C111835:CCL2 protein, human; D018932:Chemokine CCL2; D053582:Interleukin-1alpha; D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D016328:NF-kappa B; D010446:Peptide Fragments; D010455:Peptides; D014409:Tumor Necrosis Factor-alpha; C520222:shrimp anti-lipopolysaccharide factor cyclic peptide (55-76); D020929:Mitogen-Activated Protein Kinase Kinases